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Background/aim: The aim of this study was to investigate the contribution of fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) imaging in staging of pediatric osteosarcoma patients and also to evaluate the
ability of metabolic parameters from the primary tumor to predict tumor necrosis rate (TNR).
Material and methods: F-18 FDG-PET/CT imaging was performed in staging 37 pediatric osteosarcoma patients. The metabolic parameters SUVmax (maximum standardised uptake value), MTV (metabolic tumour volume), and TLG (total lesion glycolysis) were
measured from the primary tumor. TNR level of the primary tumor was histopathologically measured after standard neoadjuvant
chemotherapy treatment. The contribution of F-18 FDG-PET/CT to staging of pediatric osteosarcoma patients and the accuracy of
metabolic parameters of the primary tumor to predict TNR were analized by regression analysis.
Results: MTV and TLG of the primary tumor were found to efficiently predict histopathologic TNR, whereas SUVmax was not (P =
0.012, P = 0.027, P = 0.25, respectively). Also 5 of 12 patients (41.6%) who were initially defined as localised osteosarcoma were upstaged
in consequence of staging F-18 FDG-PET/CT findings.
Conclusion: F-18 FDG-PET/CT staging in pediatric osteosarcoma patients can effectively distinguish metastatic-localised disease.
MTV and TLG values are important parameters, which can efficiently be used to predict TNR.
Key words: Pediatric osteosarcoma, positron emission tomography, tumor necrosis rate

1. Introdution:
The most common primary malignant bone tumor in
children and young adolescents is osteosarcoma, which
is generated from mesenchymal stem cells taking part in
bone formation [1]. Metastatic dissemination is common
at the time of diagnosis and follow-up; about 80% disseminates to the lungs and 20% is detected at the time of diagnosis and is rarely observed in the bone and lymph nodes.
5-year survival is around 65%–70% in localised disease
and decrease to 20% in the presence of metastasis [1,2].
Correct staging of osteosarcoma at the time of presentation plays a crucial role in the choice of chemotherapy pro-

tocol and additional therapies, such as radiotherapy and
radionuclide therapy.
Prognostic markers used in osteosarcoma are age, sex,
localisation of tumor, size of tumor, histologic grade, stage
of disease, level of alkaline phosphatase (ALP) and lactate
dehydrogenase (LDH), and histopathologic tumor necrosis rate (TNR) after neoadjuvant therapy. TNR in osteosarcoma is a parameter indicating the degree of necrotic
tissue of the excised primary tumor post neoadjuvant
chemotherapy and has more prognostic importance in
comparison with the other markers. It is well known that
in patients with higher TNR, disease-free survival is lon-
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ger compared to those with a lower TNR; thus, adjuvant
chemotherapy protocols can be adjusted according to the
degree of TNR [3]. It has been shown in a variety of studies
that fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/
CT) imaging modality has a higher sensitivity (98% versus
83%) and specificity (97% versus 73%) in detecting distant
metastasis other than lung metastasis in primary malignant bone tumors [4]. While F-18 FDG-PET/CT and bone
scintigraphy have similar sensitivity and spesificity in detection of bone metastases in osteosarcoma, the combination of the two modalities can yield a higher sensitivity
when used together [5].
F-18 FDG-PET/CT metabolic parameters, such as
peak tumoral activity uptake known as standardised maximum uptake value (SUVmax), mean value (SUVmean),
metabolic tumor volume of viable tumor tissue (MTV),
and total lesion glycolysis (TLG) used in evaluating metabolism, can be measured semiquantitatively. The importance of SUVmax and TLG values calculated from F-18
FDG-PET/CT performed before and after chemotherapy
has been highlighted as important prognostic indicators
of progression-free and overall survival in osteosarcoma
patients [6]. Metabolic parameters of the primary tumor
in staging F-18 FDG-PET/CT has been shown to be important prognostic markers foreseeing response to neoadjuvant chemotherapy and TNR in the limited number of
studies carried out [6].
This study aimed to review retrospectively the contribution of F-18 FDG-PET/CT findings to staging and
the value of metabolic parameters of the primary tumor
to predict TNR in pediatric osteosarcoma patients staged
with F-18 FDG-PET/CT.
2. Material and methods
2.1. Patients selection
After formal institutional review board and local educational planning board approval (July 21, 2016) by the University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Training Hospital, Ankara,
Turkey, a retrospective study was conducted on a total of
37 patients from our center in the pediatric age group (618 years) with a histologic diagnosis of osteosarcoma evaluated for staging/extent of disease using F-18 FDG-PET/
CT between June 2009 and December 2016. Data collected
included age of diagnosis, histological subtype, tumor size,
location of primary disease, presence of metastatic disease
at diagnosis, histopathologic findings including TNR at resection, radiologic, scintigraphic, laboratory findings, and
neoadjuvant chemotherapy protocols.
2.2. Image review and tumor characteristics
All patients fasted for at least 6 h and had a blood glucose
level below 150 mg/dL. After being injected with 0.09–0.12
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mCi/kg intravenous F-18 FDG followed by 60 min of rest,
a whole body scan in supine position was carried out. Dual-phase imaging and/or additional images were obtained
from selected patients in case of suspicion or necessity. All
patients were evaluated using three-dimensional Siemens
Biograph True Point 6 PET/CT device. The PET scanner
and 3 mm sliced multidetector CT scanner obtained simultaneous images in the same session. Low dose CT images without intravenous iodinated contrast were used for
attenuation-correction and anatomy-correlation. All PET/
CT images were reconstructed and reviewed on Siemens
Leonardo PET/CT workstation. All metabolic parameters were taken from a volume of interest (VOI) drawn
around the primary tumoral hypermetabolic lesion with
a SUV-based automatic contouring programme. Lesion
contours were checked for neighboring normal tissue by
looking at axial, coronal, and sagittal sections and manually reshaping the VOI. The SUVmax value in the volume
of interest was recorded and a threshold SUV of 2.0 mg/
dL was used to automatically measure MTV from the
metabolically active tumor in the VOI. TLG values were
measured as a product of SUVmean and MTV. Metabolic parameters from lesions suspicious for metastasis were
also recorded.
Histological responses to preoperative chemotherapy
were assessed for operated tumor tissues, and all the tumoral tissue including the largest cross section were ascertained to evaluate the response to chemotherapy by
pathologist in our center. The response was evaluated based on percentage of tumor necrosis or viable tumor cells
as follows: good responders had equal to or greater than
90% tumor necrosis or less than 10% viable tumor cells, on
the other hand, poor responders had less than 90% tumor
necrosis or greater than 10% viable tumor cells based on
histopathological reports [7,8].
Patients were classified as localised disease (stage 1 and
2) and metastatic disease (stage 3 and 4) in osteosarcoma
with respect to the American Joint Committee on Cancer
(AJCC) criteria (Table 1). Lesions evaluated as metastasis/
suspicious for metastasis found on F-18 FDG-PET/CT
or other imaging modalities (radiologic imaging, bone
scintigraphy) were either histopathologically verified or
reevaluated and decided upon after 6-month clinical, metabolic and morphological follow-up by means of nuclear
and radiology imaging modalities. Findings obtained from
conventional radiologic and nuclear imaging modalities as
well as additional information obtained from staging F-18
FDG-PET/CT were recorded.
2.3. Statistical analysis
TNR level is one of the most independent prognostic indicators evaluated in pediatric osteosarcoma. Prediction of
TNR levels under standard therapy will provide important
information in determining the prognosis of the disease.
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In addition, the presence of metastases and the region of
metastases are parameters that should not be ignored in
determining the prognosis. The metabolic parameters of
the staging F-18 FDG-PET/CT imaging parameters (SUVmax, MTV, TLG values) ability to predict lung, lymphatic,
bone and bone marrow metastases and postchemotherapy
TNR levels (categorized higher and lower than 90%) were
determined by logistic regression analysis. The logistic
regression model was used to estimate the odds ratio (OR)
in univariate analysis. Median values were used as cut-off
values for covariates that were not normally distributed.
Statistical tests were performed using Statistical Package
for the Social Sciences (SPSS) software version 15.0 (IBM
Corp., Chicago, IL, USA). Statistical significance was set at
the 5% level.
3. Results
3.1. Patient characteristics, demographic and clinical
data
37 eligible patients (21 male (56%) and 16 female (44%))
between the ages 6–18 (mean 14) with histopathologically proven diagnosis of osteosarcoma were enrolled in this
study (Table 2). Histopathological subtypes of 37 patient’s
preoperative biopsy was high grade conventional osteosarcoma (osteoblastic and chondroblastic osteosarcoma)
in 34 of 37 patients (91.9%), parosteal osteosarcoma in
2 patients, one of which was high grade (5.4%) and low
grade periosteal osteosarcoma in 1 patient (2.7%). The location of the primary tumor was the femur in 24 patients
(64.9%), the tibia in 6 patients (16.2%), the fibula in 3 patients (8.1%), and the humerus in 4 patients (10.8%).
AJCC stages were as follows: 2 patients stage 1 (5.4%),
2 patients stage 2A (5.4%), 13 patients stage 2B (35.1), 7
patients stage 4A (18.9) and 13 patients stage 4B (35.1%).
At the time of initial staging, 17 patients (45.9%) were free
of distant metastasis and 20 patients (54.1%) had distant

metastasis. Of the 20 patients with distant metastasis 7 patients (35%) had lung metastasis, 2 of them also had intramedullary skip metastasis; 6 patients (30%) had lymphatic
metastasis, 2 of them also had intramedullary skip metastasis; 4 patients (20%) had both lung and lymphatic metastasis, 1 of them also had intramedullary skip metastasis; 3
patients (15%) had bone, lung and lymphatic metastasis, 1
of them also had intramedullary skip metastasis.
In 12 patients, F-18 FDG-PET/CT used for staging
purposes detected metastatic lymph nodes in addition to
detecting all findings of other radiological modalities performed (magnetic resonance imaging (MRI) of primary
tumor, CT evaluation of the lung), hence upstaging 5 patients (41.6%) from localised to metastatic disease status.
Staging bone scan revealed osteoblastic bone metastasis in
1 of 3 patients with metastatic disease and lung metastasis on diagnostic thorax CT evaluation. In 2 patients, F-18
FDG-PET/CT scan additionally revealed lytic bone metastasis, which was not visible on bone scan, contributing to
treatment plan and follow-up in these patients. 36 of 37
patients included in this study were treated with neoadjuvant chemotherapy, 34 patients were operated (24 patients
(64.9%) went through limb-sparing surgical procedure, 10
patients (27%) were amputated) and 3 patients were deemed inoperable due to advanced disease.
Postoperative histopathological analysis of 33 patients
was a follows: The histological subtype was high grade conventional osteosarcoma (osteoblastic and chondroblastic
osteosarcoma) in 30 patients, parosteal osteosarcoma in
2 patients, one of which was high grade and periosteal

Table 2. Patient characteristics.
Characteristic
Age, median (range)

14(6–18)

Male

21 (56%)

Female

16 (44%)

Sex
Table 1. Staging according to AJCC criteria in extremity osteosarcoma.

Values

Primary tu- Femoral
mor localiza- Tibial
tion
Fibular

24 (64.9%)

Humeral
Histopat ho- Conventional (High grade)
logical type
Parosteal

4 (10.8%)

6 (16.2%)
3 (8.1%)

Stage Tumor grade

Tumor size

Metastasis

1A

Low

≤ 8 cm

None

1B

Low

> 8 cm

None

2A

High

≤ 8 cm

None

2B

High

> 8 cm

None

Periosteal

Localised (Stage 1A-B, 2A-B) 17 (46%)

3

Low & high

Any size

Skipped metastasis

4A

Low & high

Any size

4B

Low & high

Any size

Lung metastasis
Extrapulmonary /
lymphatic metastasis

AJCC: American Joint Committee on Cancer.

Stage

Metastatic (Stage 4A-B)

< 90%
Tumor necro≥ 90%
sis rate
Unknown

2 (5.4%)
34 (91.9%)
1 (2.7%)
20 (54%)
18 (53%)
15 (44%)
1 (3%)
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osteosarcoma in 1 patient. The postoperative histopathology evaluation of 1 patient was not reviewed due to being
operated in another center, hence was excluded from the
study. Tumor necrosis rate on postoperative specimen was
of low necrosis degree (< 90%) in 18/33 patients (55%) and
high necrosis degree (≥ 90%) in 15/33 patients (45%).
3.2. The relationship between F-18 FDG-PET/CT metabolic parameters (SUVmax, MTV, TLG) and TNR
The median SUVmax value of the primary tumor in all
patients was 9.7 mg/dL, median MTV value was 249.5
mL and median TLG value was calculated as 1074 gr.
When the median value was used as a cut-off value, logistic regression analysis used to analyse the ability of these
metabolic parameters to predict tumor necrosis rate after
standard chemotherapy revealed that high SUVmax values
could not predict TNR (P = 0.25), but patients with higher
MTV and TLG values than the cut-off value were found
to have low (< 90%) degree of TNR (P = 0.012, P = 0.027,
respectively). Patients with low degree of TNR had a median SUVmax value of 10.08 mg/dL, median MTV value of
399 mL and median TLG value of 1648 gr, while patients
with high level (≥ 90%) TNR had a median SUVmax value
of 9.18 mg/dL, median MTV value of 130 mLand median
TLG value of 605 gr. As can be seen in one of the our cases we used in this study; the case is localised osteosarcoma patient whose primary tumor on right distal femur
(Figure). The tumor is visible on maximal density image
(Figure, a) and sectional views (Figure, b) in F-18 FDG-

PET/CT scan. The tumor has lower MTV (99.7 mL), TLG
(399.7 gr) and higher SUVmax (10.34 mg/dL) levels than
measured median PET metabolic parameter levels with
VOI method in F-18 FDG-PET/CT scan (Figure, b). TNR
of the patient’s tumoral lesion is 100% (higher than 90%)
after neoadjuvant therapy.
Unlike MTV and TLG, factors used in prognostification of pediatric osteosarcoma patients such as age of diagnosis, location of tumor, level of LDH-ALP, tumor grade,
tumor size, solid organ or lymphatic metastasis, and sex
were not found to predict post-therapy TNR (Table 3).
3.3. The relationship between F-18 FDG-PET/CT metabolic parameters (SUVmax, MTV, TLG) and regional
metastasis
When the median value was used as a cut-off value; in patients with MTV and TLG values higher than cut-off values, there was a greater possibility of detecting lung and
lymphatic metastasis at staging. On the other hand, these
values were not able to predict the presence of bone (P =
0.17, P = 0.08, respectively) and bone-marrow metastasis
(P = 0.09, P = 0.08, respectively). Similarly, the SUVmax
value of the primary tumor was not able to predict lung,
lymphatic, bone, or bone-marrow metastasis (P = 0.25, P
= 0.14, P = 0.27, P = 0.45, respectively) (Table 4).
4. Discussion
Osteosarcoma is the most common primary malignant
bone tumor occuring in pediatric age group and young

Figure. Localised osteosarcoma patient (12-y, m) with low metabolic parameters (MTV and TLG) of primary tumor. On staging F-18
FDG-PET/CT images; primary tumor on right distal femur: Maximal density image (a). VOI from the primary tumor (b), taken from
the axial, coronal, sagittal sections and measured metabolic parameters; SUVmax: 10.34 mg/dL, MTV: 99.7 mL, TLG: 399.7 gr. The
patient, whose TNR was 100% after neoadjuvant therapy, has been followed up for 49 months without disease. F-18 FDG-PET/CT: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; SUVmax: Maximum standardised uptake value;
MTV: Metabolic tumor volume; TLG: Total lesion glycolysis; VOI: Volume of interest; TNR: Tumor necrosis rate.
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Table 3. Parameters that predict TNR levels below 90% with univariate logistic regression analysis.
Parameters

High TNR
(n = 15)

Low TNR
(n = 18)

SUVmax

9.18 mg/dL 10.08 mg/dL

MTV

130 mL

399 mL

TLG

605 gr

1648 gr

Sex

-

-

Age

12

15

Region of
tumor

-

LDH

266 u/L

365 u/L

ALP

243 u/L

469.5 u/L

Metastasis -

-

Tumor
grade

-

-

OR (CI, 95%) P-value
1.02
(0.89–1.17)
7.10
(1.5–33.3)
5.52
(1.2–24.8)
0.71
(0.17–2.77)
1.19
(0.96–1.47)
0.81
(0.09–7.01)
0.99
(0.98–1.003)
1.004
(1.00–1.008)
4.00
(0.93–17.11)
0.82
(0.004–17.38)

0.25
0.012*
0.027*
0.61
0.3
0.32
0.79
0.08
0.06
0.82

The univariate logistic regression analysis indicate that only
MTV and TLG levels of the parameters can predict TNR. MTV:
Metabolic tumor volume; TLG: Total lesion glycolysis, TNR:
Tumor necrosis rate; SUVmax: Maximum standardised uptake
value; LDH: Lactate dehydrogenase; ALP: Alkaline phosphatase;
OR: Odds ratio, CI: Confidence interval, *P < 0.05.

adults. Metastatic disease is one of its most important
prognostic markers. While 5-year overall survival is
around 65%–70% in nonmetastatic localised disease, it can
fall to 20% in the presence of metastatic disease. Metastatic
dissemination is a common finding at time of diagnosis
and follow-up, also it occurs in lungs by 80% (20% at time
of diagnosis) and rarely to the bones and lymph nodes
[1,2]. With the development of chemotherapy protocols
and targeted treatment, there has been a significant increase in progression-free and overall survival in comparison to previous rates. Other important prognostic factors
are the tumor location, tumor size, patient age, histologic
subtype, AJCC stage, site of metastasis, extent of surgery/
type of surgery, presence of tumor at surgical margin, and
histologic response to chemotherapy [9].
Metastasis at time of diagnosis considerably decreases
progression-free and overall survival time making significant changes in the treatment plan. Accurate staging of
disease has a major effect on the selection of neoadjuvant
chemotherapy protocol and the need for adjuvant radiotherapy in case of metastasis. Current NCCN guidelines

recommends MRI and/or CT of region of disease, thorax
CT, F-18 FDG-PET/CT and/or bone scan for evaluation
of distant metastasis at initial staging of patients diagnosed with osteosarcoma [10]. F-18 FDG-PET/CT has been
shown to have superior sensitivity and specificity than
conventional radiological imaging in detecting distant
metastasis (except lung) in primary bone tumors [4]. F-18
FDG-PET/CT and other conventional imaging modalities have close diagnostic accuracy in evaluation of the
primary tumor in osteosarcoma; on the other hand, F-18
FDG-PET/CT has been shown to be superior in detecting
lymphatic dissemination (95% versus 25%) and bone metastasis. Metastatic bone lesions not visible on bone scan
can accurately be detected on F-18 FDG-PET/CT. Justly,
thin-slice CT is superior to nonenhanced, nondiagnostic
F-18 FDG-PET/CT imaging in detection of milimetric
metastatic lung nodules. On the other hand, the CT component of hybrid imaging may enable detection of lung
nodules even without FDG uptake [2,11]. In accordance
with actual data, all nodules and metastatic findings on diagnostic chest CT were consistent with F-18 FDG-PET/
CT results in all patients included in this research. In addition, 5 of 12 patients (41.6%) with lymphatic metastases
were upstaged from localised disease to metastatic disease. F-18 FDG-PET/CT made a positive contribution to
2 patients treatment plan after detecting bone metastases
of lytic character, while no pathologic findings were present on bone scan. F-18 FDG-PET/CT additionally detected findings consistent with intramedullary bone marrow
metastasis in 6 patients further contributing to defining
extent of disease.
Current study data support that metabolic parameters
from F-18 FDG-PET/CT imaging modality can be used to
predict progression-free and overall survival. Despite the
presence of multiple studies claiming metabolic parameters success in determining prognosis, to the best of our
knowledge, there are no more studies proving the relation
between these parameters and stage of disease at time of
diagnosis. An increase in the level of SUVmax, MTV, and
TLG is observed as the level of aggression and size of the
primary tumor increases and an increased likelihood of
detecting metastasis during staging of follow-up is present
in these patients. The results of this study concluded that
while there is a greater probability of existence of lung and/
or lymphatic metastasis with high MTV and TLG values
of the primary tumor in osteosarcoma patients, these parameters can not efficiently predict the presence of bone
and/or bone marrow metastasis. This study also concludes
that TLG is a more reliable prognostic marker than SUVmax in patients with lung and lymphatic metastasis. This
can be explained by TLG being a parameter directly related to both the tumor volume and metabolic activity, also
while SUVmax represents a very small area of the tumor,
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Table 4. Regional metastasis prediction level of PET metabolic parameters.
Region of metastasis
Lung

Lymphatic

Bone marrow

Bone

SUVmax

MTV

TLG

met. (+) n = 15

13.3 mg/dL

400 mL

1930 gr

met. (–) n = 22

8.9 mg/dL

137 mL

618 gr

OR (CI, 95%)

0.82 (0.78–1.12)

2.32 (1.35–5.94)

1.86 (1.12–3.64)

p-value

0.25

0.001*

0.001*

met. (+) n = 12

13.8 mg/dL

458 mL

2163 gr

met. (–) n = 25

9.18 mg/dL

157 mL

716 gr

OR (CI, 95%)

0.79 (0.71–1.24)

2.17 (1.23–4.67)

1.79 (1.08–3.44)

p-value

0.14

0.001*

0.001*

met. (+) n = 6

13 mg/dL

447 mL

1878 gr

met. (–) n = 31

9.7 mg/dL

228 mL

1057 gr

OR (CI, 95%)

1.06 (0.92–1.18)

0.85 (0.67–1.18)

0.96 (0.80–1.31)

p–value

0.45

0.09

0.08

met. (+) n = 3

13.9 mg/dL

394 mL

1930 gr

met. (–) n = 34

9.67 mg/dL

238 mL

1140 gr

OR (CI, 95%)

0.89 (0.76–1.12)

1.02 (0.97–1.43)

0.74 (0.70–1.27)

p-value

0.27

0.17

0.08

The univariate logistic regression analysis to determine the prediction of PET metabolic parameters of primary tumor to other body
build metastasis. It has been stated that MTV and TLG predict lung and lymphatic mestastasis, unlike other parameters. PET: Positron
emission tomography; SUVmax: Maximum standardised uptake value; MTV: Metabolic tumor volume; TLG: Total lesion glycolysis;
met.: Metastasis; OR: Odds ratio, CI: Confidence interval; *P < 0.05.

TLG represents a greater area of the tumor tissue hence
providing metabolic data.
It is known that osteosarcoma patients with a low TNR
have a worse prognosis post neoadjuvant chemotherapy
[12, 13]. In a study about the relationship between metabolic parameters SUVmax and TLG derived from staging
F-18 FDG-PET/CT and TNR in patients receiving standard chemotherapy, Costelloe et al. stated that, TNR (above and below 90%) can be predicted by TLG but could not
be predicted by SUVmax levels (P = 0.05, P = 0.62, respectively). High degree of TNR (above 90%) is seen in cases with lower TLG values [6]. This study also came to the
conclusion that while SUVmax values do not predict TNR
(P = 0.25), high TLG values are able to predict TNR (<
90% necrosis) (P = 0.027). Our study also concludes that
MTV values can predict TNR, which is lower in patients
with higher MTV values besides TLG (P = 0.012). Similarly, Davis et al. presented a study of 34 pediatric osteosarcoma patients and found that SUVmax values are not
effective in predicting TNR but that SUVmax derived from
interim F-18 FDG-PET/CT imaging on the 5th and 10th
weeks of neoadjuvant chemotherapy can be more efficient
in predicting TNR [14].
Current guidelines and studies recommend continuation of therapy if there is a positive response to therapy
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which means viable tumor cells are below 10% in operation material after extensive resection in both localised
and metastatic osteosarcoma patients. On the other hand,
in case of a poor response it is recommended to change
the therapy possibly to a more aggressive regimen [12,13].
Deley et al. found a statistically significant increase in TNR
when second line therapy regimens etoposide and ifosfamide where used in addition to methotrexate and doxorubicin in osteosarcoma therapy [15]. Accordingly, Goorin
et al. showed that when therapy was changed to high doses
of second line regimens such as ifosfamide and etoposide,
an improvement was observed in therapy response parameters such as TNR and radiological response criteria.
Of the 43 pediatric osteosarcoma patients included in this
study, TNR was 100% in 4 patients, 90%–99% in 19 patients; therefore, 59% high histological response level was
reached in patients in total [16].
Although second line/aggressive chemotherapy protocols managed an increase in TNR, not all patients can
be candidates for this kind of therapy due to increase in
toxic side effects. Therefore, it sould be important to decide which patients would be able to benefit from second
line treatment after staging. In our study, by proving that
lower levels of TNR can be foreseen in patients with higher
metabolic parameters (MTV and TLG), and by using this

FİDAN et al. / Turk J Med Sci
parameters, we can confidently make the decision to change therapy protocols, which aim to increase TNR hence
contributing to overall survival.
F-18 FDG-PET/CT is efficiently used in evaluating
response to therapy in lymphoma and many solid tumors
[17]. An interim F-18 FDG-PET/CT is possible to evaluate
response to treatment early on in patients receiving one or
two courses of neoadjuvant chemotherapy. Current NCCN
guidelines and studies state that interim F-18 FDG-PET/
CT is useful in both evaluation of response to therapy
and in use as a prognostic marker of progression free and
overall survival [18–20]. There has been an increase in research of the relationship between the ratio of change in
SUVmax, MTV and TLG (staging and post-therapy values), TNR-histopathological response [6,21–24]. Also, the
relation between change in metabolic parameters post-neoadjuvant chemotherapy and progression-free and overall
survival are amongst new study areas [6,24]. In a study on
40 pediatric-adolescent osteosarcoma patients by Hawkins
et al. higher TNR was found in patients with SUV2/SUV1
(change in SUVmax before and after chemotherapy) below
0.5 or post neoadjuvant chemotherapy SUVmax (SUV2)
less than 2 mg/dL. Also, patients with high level TNR and
SUV2 values lower that 2.5 mg/dL were reported as having longer progression free survival [24]. In a study by Im
et al. with 14 patients, F-18 FDG-PET/CT was performed
prior to neoadjuvant therapy, after one cycle of therapy
(interim) and at end of therapy. MTV and TLG values at
interim and end of therapy were compared with initial values and a positive correlation was found between the ratio
of change of MTV and TLG and TNR. A high level TNR
(90%–100%) has been shown in patients with SUVmax values below 3.0 mg/dL postchemotherapy with 100% sensitivity and 89% specifity [25]. Thus, F-18 FDG-PET/CT

metabolic parameters from staging, interim, and response
to therapy provide important prognostic information by
predicting TNR and progression free and overall survival
rates in osteosarcoma patients.
The present study has several limitations. First, only
staging F-18 FDG-PET/CT imaging and not interim and/
or end of therapy F-18 FDG-PET/CT was available in
our study group, which restricted our comparing ratio of
change in metabolic parameters with predicting histopathological response. Second, histopathological verification
was not performed to all metastatic findings. The decision was made based on clinical follow-up and additional
imaging modalities. Finally, the patient inclusion criteria
could have had a better standardisation if the study was
prospective instead of retrospective. The issues we emphasize in our study need to be supported by prospective
studies in larger series.
As a result, in pediatric osteosarcoma patients staging
whole body F-18 FDG-PET/CT imaging has been shown
to accurately distinguish metastatic and localised disease
and effectively contribute to staging. In addition, it has
shown that the metabolic parameters (MTV and TLG) of
the primary tumor are important and accurate parameters
used to predict postchemotherapy TNR.
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